Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

December 19, 2018

Study Completion Date

December 19, 2018

Conditions
Hepatitis C, Chronic
Interventions
DRUG

glecaprevir (300mg)/pibrentasvir (120mg)

glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks

Trial Locations (33)

1142

Auckland City Hospital, Auckland

2010

East Sydney Doctors, Sydney

St Vincent's Hospital Sydney, Sydney

3004

The Alfred Hospital, Melbourne

3010

Inselspital - Universitaetsspital Bern, Bern

3065

St Vincent's Hospital Melbourne, Melbourne

8091

University Hospital Zurich, Zurich

10016

New York University Langone Medical Center, New York

10439

zibp - Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH, Berlin

13008

Hopital Saint Joseph, Marseille

27710

Duke University Medical Center, Durham

30625

Hannover Medical School, Hanover

40237

Center for HIV and Hepatogastroenterology, Düsseldorf

48143

CIM-Centrum fuer Interdisziplinaere Medizin GmbH, Münster

53715

SSM Health Dean Medical Group, Madison

75012

Hopital Saint Antoine, Paris

94000

Hopital Henri Mondor, Créteil

02215

Beth Israel Deaconess Medical Center, Boston

Unknown

Holdsworth House Medical Practice, Sydney

Royal Adelaide Hospital, Adelaide

Calder Center, Auckland

Christchurch Hospital, Christchurch

Dunedin Hospital, Dunedin

V5Z 1H2

Lair Centre, Vancouver

V6Z 2K5

(G.I.R.I.) GI Research Institute, Vancouver

L6R 3J7

William Osler Health System, Brampton

L8N 4A6

St Joseph's Healthcare Hamilton, Hamilton

ON M57 2S8

Toronto General Hospital, Toronto

H4A 3J1

McGill University Health Centre (MUHC), Montreal

G1V 4G2

CHU de Québec-Université Laval, Québec

E1 1BB

Barts Health, London

SE5 9RS

King's College Hospital, London

W2 1NY

Imperial College Healthcare NHS Trust (St Mary's Hospital), London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kirby Institute

OTHER_GOV

NCT03117569 - Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients | Biotech Hunter | Biotech Hunter